Banca de QUALIFICAÇÃO: ANTONIO ALVES DE SOUZA NETO

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : ANTONIO ALVES DE SOUZA NETO
DATE: 15/07/2025
TIME: 14:00
LOCAL: Sala de Aulas II GEP/MEJC
TITLE:

Efficacy and safety of human papillomavirus vaccination in patients with human immunodeficiency virus: an overview and network meta-analysis overview

KEY WORDS:

Papillomavirus vaccines; Vaccine efficacy; HIV.

PAGES: 45
BIG AREA: Ciências da Saúde
AREA: Medicina
SUMMARY:

Introduction: Human papillomavirus (HPV) is the most common sexually transmitted infection and is associated with cervical cancer and genital warts. Prophylactic HPV vaccines approved by the FDA offer protection against high-risk HPV types and have shown proven efficacy over a period of 8 to 14 years. Although these vaccines are generally safe and effective, their efficacy and safety in People Living with Human Immunodeficiency Virus (PLHIV) remain uncertain, despite the increased risk of HPV-related cancers in this population. Objective: This review aims to evaluate the efficacy and safety of HPV vaccination in PLHIV. Methods: This overview was developed following the Preferred Reporting Items for Systematic Reviews and incorporating Network Meta-Analyses (PRISMA-NMA). An electronic search without date or language restrictions was conducted in multiple databases using keywords related to HPV vaccines and their efficacy and safety. We included systematic reviews and randomized controlled trials (RCTs) involving PLHIV who received bivalent, quadrivalent, or nonavalent HPV vaccines. Study selection for title and abstract screening was conducted independently by two researchers using Rayyan software, with discrepancies resolved by consensus with a third author. Data extraction, including study outcomes such as seroconversion, antibody titers, and side effects, was performed by two researchers, with unresolved issues reviewed by a third reviewer. Risk of bias was assessed using AMSTAR 2. Quantitative synthesis was conducted using R software, with results analyzed using appropriate statistical models based on heterogeneity. The certainty of evidence was assessed using CINeMA. Conclusions: The quadrivalent HPV vaccine (qHPV) showed a better safety profile regarding pain, including across all doses. For other adverse effects, no significant differences were observed between groups. Regarding immunological efficacy, no significant differences were found between qHPV-vaccinated and unvaccinated patients for HPV types 6, 11, 16, and 18.

COMMITTEE MEMBERS:
Externa à Instituição - ANA PAULA FERREIRA COSTA - LNRCC
Presidente - 1055045 - MARCELA ABBOTT GALVAO URURAHY